Placeholder canvas

COVID-19 Vaccine | Gap between two Covishield doses extended to 12-16 weeks in India

The Centre on May 13 accepted the recommendation made by an expert panel to increase the gap between two Covishield vaccine doses to 12-16 weeks.

The two jabs of the Serum Institute of India (SII)-manufactured vaccine were earlier administered at a gap of six-to-eight weeks.

The National Technical Advisory Group on Immunisation (NTAGI) suggested the increase in dosage interval to the Centre’s COVID-19 Working Group, claiming that it would provide “better results”.

Based on the available real-life evidence, particularly from the UK, the COVID-19 Working Group agreed for increasing the interval to 12-16 weeks between two doses of Covishield vaccine, the Centre stated in an official release.

The recommendation of the COVID-19 Working Group – to increase the Covishield dose interval gap – was accepted by the National Expert Group on Vaccine Administration for Covid-19 (NEGVAC), the top government advisory body, on May 12. Subsequently, the Union Health Ministry also gave its nod.

“The Union Ministry of Health and Family Welfare has accepted the recommendation of the COVID Working Group for extension of the gap between the first and second doses of Covishield vaccine to 12 -16 weeks,” the official release stated.

The COVID-19 Working Group, however, has not recommended any change in an interval of Covaxin vaccine doses, which are administered at a gap of four to six weeks.

Notably, Covaxin and Covishield are the two vaccines being currently administered to beneficiaries in India. The dose interval gap for the latter was increased from 28 days to six-to-eight weeks in March, based on the recommendation of the World Health Organisation (WHO). With the fresh revision, it has now been further extended to 12-16 weeks.

The decision to increase the gap also comes amid reports of vaccine shortages in several states. Maharashtra, the state worst-affected by the second pandemic wave, announced on May 11 that it would be prioritising the second doses for the 45-plus age group by temporarily pausing the immunisation drive 18-44 age group.

Share your love
Facebook
Twitter
LinkedIn
WhatsApp

Newsletter

Follow Us

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

error: Unauthorized Content Copy Is Not Allowed